基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抑制剂 血管生成(Angiogenesis) FGFR 抑制剂 AZD-4547 化合物 AZD4547
  • 化合物 AZD4547|T1948|TargetMol

化合物 AZD4547|T1948|TargetMol

AZD4547
1035270-39-3
263 1mg 起订
371 2mg 起订
617 5mg 起订
上海 更新日期:2024-09-23

TargetMol中国(陶术生物)

VIP12年
联系人:邵小姐
电话:021-021-33632979拨打
手机:15002134094 拨打
邮箱:marketing@targetmol.com

产品详情:

中文名称:
化合物 AZD4547
英文名称:
AZD4547
CAS号:
1035270-39-3
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.83%
产品类别:
抑制剂
货号:
T1948

Product Introduction

Bioactivity

名称AZD4547
描述AZD4547 is an FGFR family inhibitor. AZD4547 selectively inhibits FGFR1 phosphorylation and suppresses cancer cell proliferation through inhibition of FGFR1 signaling, and is able to act on FGFR1 (IC50:0.2 nM), FGFR2 (IC50:2.5 nM), FGFR3 (IC50:1.8 nM) and FGFR4 (IC50:165 nM). IC50:165 nM).[2]
细胞实验Cell lines were incubated with fixed concentrations of AZD4547 for 72 hours. For fluorescence-activated cell sorting (FACS), cells were fixed with 70% ethanol and then incubated with propidium iodide/RNase A labeling solution. Cell-cycle profiles were assessed with a FACSCalibur instrument and CellQuest analysis software. For apoptotic analysis, cells and media were gently harvested and centrifuged, followed by washing of cell pellets. Cells were then processed for Annexin V-fluorescein isothiocyanate (FITC) staining and propidium iodide uptake according to the manufacturer's instructions. The proportion of cells staining positive for Annexin V were then assessed with a FACSCalibur instrument and quadrant sorting was done by CellQuest analysis software [1].
激酶实验Cells were treated with AZD4547 or control for 3 hours at 37°C and then stimulated with 10 ng/mL aFGF/bFGF and 10 μg/mL heparin for 20 minutes. Western blotting was conducted with standard SDS-PAGE procedures and antibody incubation carried out overnight at 4°C. Secondary antibodies were applied and immunoreactive proteins visualized with Chemiluminescence substrate according to the manufacturer's instructions [1].
动物实验Tumor xenografts were established by s.c. injection into the left flank with 0.1 mL tumor cells (1 × 10^6 for LoVo, 1 × 10^7 for HCT-15, and 1 × 10^7 for Calu-6) or 0.2 mL (2 × 10^7 for KMS11 and KG1a) mixed 1:1 with Matrigel, with the exception of LoVo and HCT-15, which did not include Matrigel. Mice were randomized into control and treatment groups when tumors reached the determined size of more than 0.2 cm3. Tumor volume (measured by caliper), animal body weight, and tumor condition were recorded twice weekly for the duration of the study. Tumor volume was calculated as described previously [1].
体外活性方法:NRK-52E细胞用2.5,5,10,20μM AZD4547预处理1小时,然后暴露于0.5μg/ mLLPS指定时间,观察AZD4547对NRK-52E细胞中 LPS 诱导的炎症缺陷。 结果:AZD4547在NRK-52E细胞中以20μM的浓度显著抑制细胞增殖。[2] 方法:NRK-52E细胞用10μM AZD4547预处理1小时,然后暴露于0.5μg/ mL LPS指定时间,研究了 NRK-52E 细胞中促炎因子的水平。 结果:AZD4547通过减少NRK-52E细胞中的TAK1/NF-κB信号通路来减弱LPS诱导的炎症因子。[2]
体内活性方法:C57BL/6 小鼠使用LPS(15 mg/kg,腹膜内注射)并用AZD4547治疗(在LPS治疗前1小时灌胃40 mg/kg),研究 AZD4547 在 LPS 诱导的急性肾损伤中的肾保护作用以及测量了促凋亡基因Bax和抗凋亡基因Bcl-2研究AZD4547对AKI中保留肾功能的影响是否通过调节细胞凋亡来介导。 结果:AZD4547可以预防LPS相关的肾功能不全,细胞凋亡和小鼠肾脏炎症。[1]
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 50 mg/mL (107.86 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
关键字Inhibitor | Fibroblast growth factor receptor | FGFR | AZD 4547 | inhibit | AZD-4547 | AZD4547
相关产品Amlexanox | Ribociclib | Formononetin | Axitinib | Sorafenib tosylate | Lenvatinib mesylate | Ferulic Acid | Regorafenib | Pazopanib | Nintedanib | Sorafenib | Regorafenib monohydrate
相关库抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | 激酶抑制剂库 | 膜蛋白靶向化合物库 | 酪氨酸激酶分子库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库
AZD4547|TargetMol

公司简介

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起,为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部,化学事业部,生物事业部和新材料部。 从虚拟筛选到实体化合物分子供应;从商业化产品销售到个性化定制合成;从对明确靶点的分子筛选到对明确分子的多靶点筛选,从高通量筛选到化学结构优化,我们都可以满足您的科研用品及技术服务的需求。 经过在中国市场五年的精心耕耘,我们已成为筛选化合物领域优秀的供应商,为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期 (12年)
注册资本 566.2651万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,试剂,定制,服务
主营行业 化学试剂,生物活性小分子

化合物 AZD4547相关厂家报价

  • AZD4547;
  • AZD4547;
  • 湖北诺迪纳生物技术有限公司 VIP
  • 2024-10-21
  • 询价
  • AZD4547
  • AZD4547
  • 南京百鑫德诺生物科技有限公司
  • 2024-09-26
  • 询价
  • AZD4547
  • AZD4547
  • 汇聚化学(上海)有限公司
  • 2022-02-24
  • 询价
内容声明
拨打电话 立即询价